22/12/2020 FDA approves Vertex’s TRIKAFTA®, SYMDEKO® and KALYDECO® for use in people with cystic fibrosis with certain rare mutations News
22/12/2020 Ligand’s Icagen and GSK enter global collaboration and license agreement to target neurological disorders News
21/12/2020 Chief Scientific Officer at Nanion, Andrea Brüggemann, on automated patch clamp in academia, ion channel industry and fundraising Interviews
18/12/2020 Soricimed to investigate the potential benefit of its TRPV6 inhibitor, SOR-C13, in the treatment of COVID-19 News
16/12/2020 Kineta initiates Phase 1 clinical trial of its nAChR antagonist, KCP506, for the treatment of chronic pain News
12/12/2020 QurAlis’ selective KCNQ2/3 opener, QRA-244, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to retigabine News
19/11/2020 Caraway Therapeutics receives research grant from the Michael J. Fox Foundation to further study the role of TMEM175 in Parkinson’s disease News
10/11/2020 Former Nature editor Lesley Anson on publishing in high-profile journals and the future of scientific publishing Interviews
07/11/2020 Saniona regains GABAa5 negative allosteric modulator program from Boehringer Ingelheim News
27/10/2020 VP R&D and Marketing at Sophion, Thomas Binzer, on automated patch clamp, marketing in science and building bridges with academia Interviews
26/10/2020 Metrion Biosciences and Grünenthal Group extended their ion channel drug discovery collaboration News
15/10/2020 Daewoong Pharmaceutical spins off its ion channel R&D unit into a new company iN Therapeutics News
09/10/2020 Knopp Biosciences has entered the second year of the NIH-funded research to discover non-opioid treatments for chronic pain News
08/10/2020 Kineta and Genentech extended research collaboration to develop a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain News
06/10/2020 NMD Pharma Announces First Subject Dosed in a Combined Phase I/IIa Clinical Trial of ClC-1 Channel Inhibitor, NMD670, for the Treatment of Symptoms of Myasthenia Gravis News
30/09/2020 selectION Secures $5M Promissory Note to advance its Kv1.3-selective peptide blocker into clinical development News
28/09/2020 Sophion Bioscience Strengthens its Team by appointing Damian Bell as Director of Scientific Affairs News
22/09/2020 Algiax Pharmaceuticals has begun enrolling patients in a Phase IIa Proof-of-Concept Study evaluating GABAA receptor modulator, AP-325, in Chronic Neuropathic Pain News
15/09/2020 Chief Commercial Officer at AnaBios, Chris Mathes, on his career, the automated patch clamp race and experiments with human cells Interviews
11/09/2020 Casma Therapeutics has raised $50 Million to advance its TRPML1 agonist for the treatment of muscular dystrophy News
03/09/2020 VistaGen announces positive results from second preclinical study of AV-101, an NMDAR antagonist, in combination with probenecid News
02/09/2020 Nocion Therapeutics initiated a Phase 1 clinical trial of its novel small molecule charged sodium channel blocker for the treatment of cough News
01/09/2020 Professor Fredrik Elinder on ion channels in Sweden, the new open-access journal Physiologica and ultramarathons Interviews
17/08/2020 Enterprise Therapeutics initiates a Phase I study of its novel TMEM16A potentiator, ETD002, for the treatment of cystic fibrosis News
12/08/2020 Kineta is about to initiate Phase 1 clinical trials of its α9α10 nAChR antagonist KCP506 for the treatment of chronic neuropathic pain News
21/07/2020 FDA approved QUTENZA® (capsaicin) patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet News
16/07/2020 CalciMedica’s CRAC inhibitor Auxora™ shows promise as a treatment for severe COVID-19 pneumonia News
14/07/2020 NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis News
06/07/2020 BELLUS Health reports topline results from its Phase 2 trial of BLU-5937, a P2X3 antagonist, for the treatment of chronic cough News
30/06/2020 Goldfinch Bio has raised $100 Million to support the advancement of its TRPC5 inhibitor and cannabinoid receptor 1 inverse agonist for the treatment of kidney diseases News
23/06/2020 Computational biophysicist Lucie Delemotte on ion channel simulations, coronavirus and kickboxing Interviews
18/06/2020 Engrail Therapeutics Raises $32 Million in Series A Financing to develop neuroscience therapeutics News
09/06/2020 Maryland professor Andrea Meredith on BK channelopathies, her KCNMA1 foundation and patching on sewing machines Interviews
29/05/2020 Ligand expanded Icagen’s collaboration with Roche to develop ion channel modulators for the treatment of neurological disorders News
27/05/2020 Ardem Patapoutian and David Julius have won the 2020 Kavli Prize in Neuroscience “for their transformative discovery of receptors for temperature and pressure.” News
22/05/2020 CalciMedica Raises $15 Million to support ongoing clinical trials in patients with COVID-19 pneumonia News
20/05/2020 CODA Biotherapeutics collaborates with the Facial Pain Research Foundation to develop treatments for neuropathic pain News
13/05/2020 Head of Electrophysiology at IONTAS, Damian Bell, on ion channel antibodies, automated patch clamp and his obsession with ion channels Interviews
04/05/2020 Praxis has raised over $100 Million to advance its ion channel modulators for the treatment of neurological disorders News
04/05/2020 Autifony Therapeutics initiates a Phase I study of its novel Kv3 modulator for schizophrenia and hearing disorders News
20/04/2020 Professor Hugues Abriel on ion channels in Switzerland, crowdfunding, and ethical aspects of science Interviews
26/03/2020 Saniona enters into second collaboration agreement with Boehringer Ingelheim in schizophrenia News
25/03/2020 Redpin Therapeutics has raised $15.5M to advance the development of its ion channel-based chemogenetics platform News
17/03/2020 Merck announces positive results from Phase 3 trials evaluating Gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough News
10/03/2020 Asana BioSciences announces positive results from Phase 1b trials evaluating their sodium channel blocker, ASN008, for the treatment of pruritus in atopic dermatitis News
14/02/2020 Ligand Pharmaceuticals will acquire core assets, partnered programs and ion channel technologies from Icagen News
25/01/2020 Cadent Therapeutics announced that FDA accepted its IND application for SK channel modulator for the treatment of spinocerebellar ataxia News
Artem Kondratskyi 
